About Fondazione GIMEMA - Franco Mandelli Onlus
Fondazione GIMEMA - Franco Mandelli Onlus: Advancing Independent Clinical Research on Blood Diseases
Fondazione GIMEMA - Franco Mandelli Onlus is a non-profit organization that promotes, manages, and coordinates independent clinical research protocols on blood diseases. The foundation was established in 1992 by Professor Franco Mandelli, a renowned hematologist who dedicated his life to advancing the understanding and treatment of blood disorders.
The mission of Fondazione GIMEMA is to improve the quality of life and survival rates of patients with blood diseases through innovative research. The foundation collaborates with leading national and international institutions, including universities, hospitals, and research centers to conduct clinical trials that aim to develop new therapies for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), aplastic anemia (AA), and other hematological malignancies.
Fondazione GIMEMA has a team of highly qualified researchers who are committed to conducting rigorous scientific studies that adhere to ethical principles. The foundation's research activities are overseen by an independent scientific committee composed of experts in hematology, oncology, biostatistics, pharmacology, and other related fields.
One of the key strengths of Fondazione GIMEMA is its ability to bring together different stakeholders in the field of hematology. The foundation works closely with patient associations to ensure that their voices are heard throughout the research process. Moreover, Fondazione GIMEMA collaborates with pharmaceutical companies to facilitate access to new drugs for patients participating in clinical trials.
Over the years since its inception in 1992 until now Fondazione Gimema has conducted numerous clinical trials which have led not only led significant advancements but also contributed significantly towards improving patient outcomes. Some notable achievements include:
- Development of new treatments for acute promyelocytic leukemia (APL) which have increased survival rates from less than 30% before 1995 up-to over 80% today.
- Development Of New Therapies For Multiple Myeloma Which Have Significantly Improved Patient Outcomes.
- Identification Of New Prognostic Factors In Acute Lymphoblastic Leukemia Which Have Helped To Tailor Treatment Strategies For Individual Patients.
- Establishment Of A National Registry For Patients With MDS And AA Which Has Enabled Researchers To Better Understand These Rare Diseases And Develop More Effective Treatments.
In conclusion,Fondazione Gimema plays a crucial role in advancing independent clinical research on blood diseases through its commitment towards developing innovative therapies aimed at improving patient outcomes.The Foundation's dedication towards conducting rigorous scientific studies while adhering strictly ethical principles makes it one among few organizations globally whose work can be trusted without any doubt or question marks.Furthermore,the collaboration between different stakeholders such as patient associations & pharmaceutical companies ensures that all parties involved work together towards achieving common goals thereby making it possible for more people suffering from these conditions get access better treatments & care options available today.